References
- Barry JD, McCulloch R. 2001. Antigenic variation in trypanosomes: enhanced phenotypic variation in a eukaryotic parasite. Adv Parasitol. 49:1–70.
- Boots AW, Wilms LC, Swennen EL, Kleinjans JC, Bast A, Haenen GR. 2008. In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition. 24(7-8):703–710.
- Chou TC. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 58(3):621–681.
- Chou TC. 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70(2):440–446.
- Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
- Davoodvandi A, Shabani Varkani M, Clark CCT, Jafarnejad S. 2020. Quercetin as an anticancer agent: Focus on esophageal cancer. J Food Biochem. 44(9):e13374.
- Derosa G, Maffioli P, D'Angelo A, Di Pierro F. 2021. A role for quercetin in coronavirus disease 2019 (COVID-19). Phytother Res. 35(3):1230–1236.
- Elizondo-Luévano J-H, Hernández-García M-E, Pérez-Narváez O-A, Castro-Ríos R, Chávez-Montes A. 2020. Berberina, curcumina y quercetina como potenciales agentes con capacidad antiparasitaria. Rev Biol Trop. 68:1241–1249.
- Ettari R, Previti S, Di Chio C, Maiorana S, Allegra A, Schirmeister T, Zappalà M. 2020. Drug synergism: Studies of combination of RK-52 and curcumin against rhodesain of Trypanosoma brucei rhodesiense. ACS Med Chem Lett. 11(5):806–810.
- Ettari R, Previti S, Maiorana S, Allegra A, Schirmeister T, Grasso S, Zappalà M. 2019. Drug combination studies of curcumin and genistein against rhodesain of Trypanosoma brucei rhodesiense. Nat Prod Res. 33(24):3577–3581.
- Ettari R, Previti S, Maiorana S, Amendola G, Wagner A, Cosconati S, Schirmeister T, Hellmich UA, Zappalà M. 2019. Optimization strategy of novel peptide-based Michael acceptors for the treatment of Human African Trypanosomiasis. J Med Chem. 62(23):10617–10629.
- Ettari R, Previti S, Tamborini L, Cullia G, Grasso S, Zappalà M. 2016. The inhibition of cysteine proteases rhodesain and TbCatB: a valuable approach to treat Human African Trypanosomiasis. Mini Rev Med Chem. 16(17):1374–1391.
- Ettari R, Tamborini L, Angelo IC, Micale N, Pinto A, De Micheli C, Conti P. 2013. Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis. J Med Chem. 56(14):5637–5658.
- Faixova D, Hrckova G, Macak Kubaskova T, Mudronova D. 2021. Antiparasitic effects of selected isoflavones on flatworms. Helminthologia. 58(1):1–16.
- Human African Trypanosomiasis. 2017. Geneva: World Health Organization; [accessed 2021 Apr 14]. https://www.who.int/trypanosomiasis_african/en/.
- Lalmanach G, Boulange A, Serveau C, Lecaille F, Scharfstein J, Gauthier F, Authie E. 2002. Congopain from Trypanosoma congolense: drug target and vaccine candidate. Biol Chem. 383(5):739–749.
- Mead J, McNair N. 2006. Antiparasitic activity of flavonoids and isoflavones against Cryptosporidium parvum and Encephalitozoon intestinalis. FEMS Microbiol Lett. 259(1):153–157.
- Nikolskaia OV, de Lima AAP, Kim YV, Lonsdale-Eccles JD, Fukuma T, Scharfstein J, Grab DJ. 2006. Blood-brain barrier traversal by African trypanosomes requires calcium signaling induced by parasite cysteine protease. J Clin Invest. 116(10):2739–2747.
- Ortiz S, Vasquez-Ocmin PG, Cojean S, Bouzidi C, Michel S, Figadere B, Grougnet R, Boutefnouchet S, Maciuk A. 2020. Correlation study on methoxylation pattern of flavonoids and their heme-targeted antiplasmodial activity. Bioorg Chem. 104:104243.